pubmed-article:11895791 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:11895791 | lifeskim:mentions | umls-concept:C0679729 | lld:lifeskim |
pubmed-article:11895791 | lifeskim:mentions | umls-concept:C0008976 | lld:lifeskim |
pubmed-article:11895791 | lifeskim:mentions | umls-concept:C1333782 | lld:lifeskim |
pubmed-article:11895791 | lifeskim:mentions | umls-concept:C1522577 | lld:lifeskim |
pubmed-article:11895791 | lifeskim:mentions | umls-concept:C1521991 | lld:lifeskim |
pubmed-article:11895791 | lifeskim:mentions | umls-concept:C0936012 | lld:lifeskim |
pubmed-article:11895791 | pubmed:issue | 7 | lld:pubmed |
pubmed-article:11895791 | pubmed:dateCreated | 2002-3-15 | lld:pubmed |
pubmed-article:11895791 | pubmed:abstractText | Gastric marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT)-type can regress after anti-Helicobacter pylori treatment. The International Extranodal Lymphoma Study Group, the United Kingdom Lymphoma Group, and the Groupe d'Etude des Lymphomes de l'Adulte have conducted a trial to ascertain whether the addition of chlorambucil is of benefit after anti-H pylori therapy. At the last interim analysis, 105 (55%) of 189 patients had achieved a complete histologic remission after anti-Helicobacter therapy. To further assess the ability of treatment to eradicate the lymphoma clone, we analyzed the gastric biopsies from a subset of the patients by polymerase chain reaction (PCR) targeted to the immunoglobulin heavy chain genes as a molecular marker for minimal residual disease. Sixty-two cases were examined at diagnosis. Fifty-four cases were monoclonal by PCR. Forty-two of these patients achieved histologic complete remission (hCR) after anti-Helicobacter treatment: 34 cases underwent molecular follow-up analysis. Fifteen patients (44%) were in molecular remission with a median follow-up of 2 years after antibiotic treatment and of 1 year after the achievement of hCR. Less than half of the patients with MALT lymphoma can achieve sustained molecular remission after anti-Helicobacter therapy. The presence of molecular disease in the absence of histologic disease does not appear to be associated with histologic relapse, but, given the indolent nature of MALT lymphomas, a longer follow-up is needed. | lld:pubmed |
pubmed-article:11895791 | pubmed:language | eng | lld:pubmed |
pubmed-article:11895791 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11895791 | pubmed:citationSubset | AIM | lld:pubmed |
pubmed-article:11895791 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11895791 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11895791 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11895791 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:11895791 | pubmed:month | Apr | lld:pubmed |
pubmed-article:11895791 | pubmed:issn | 0006-4971 | lld:pubmed |
pubmed-article:11895791 | pubmed:author | pubmed-author:BathP EPE | lld:pubmed |
pubmed-article:11895791 | pubmed:author | pubmed-author:CotterFinbarr... | lld:pubmed |
pubmed-article:11895791 | pubmed:author | pubmed-author:GiardiniRober... | lld:pubmed |
pubmed-article:11895791 | pubmed:author | pubmed-author:PonzoniMauril... | lld:pubmed |
pubmed-article:11895791 | pubmed:author | pubmed-author:CazzanigaGiov... | lld:pubmed |
pubmed-article:11895791 | pubmed:author | pubmed-author:BiondiAndreaA | lld:pubmed |
pubmed-article:11895791 | pubmed:author | pubmed-author:BertoniFrance... | lld:pubmed |
pubmed-article:11895791 | pubmed:author | pubmed-author:ConconiAnnari... | lld:pubmed |
pubmed-article:11895791 | pubmed:author | pubmed-author:CapellaCarloC | lld:pubmed |
pubmed-article:11895791 | pubmed:author | pubmed-author:MottaTeresioT | lld:pubmed |
pubmed-article:11895791 | pubmed:author | pubmed-author:PedrinisEnnio... | lld:pubmed |
pubmed-article:11895791 | pubmed:author | pubmed-author:NoveroDomenic... | lld:pubmed |
pubmed-article:11895791 | pubmed:author | pubmed-author:RinaldiPaoloP | lld:pubmed |
pubmed-article:11895791 | pubmed:author | pubmed-author:WotherspoonAn... | lld:pubmed |
pubmed-article:11895791 | pubmed:author | pubmed-author:HancockBarry... | lld:pubmed |
pubmed-article:11895791 | pubmed:author | pubmed-author:SmithPaulP | lld:pubmed |
pubmed-article:11895791 | pubmed:author | pubmed-author:SouhamiRobert... | lld:pubmed |
pubmed-article:11895791 | pubmed:author | pubmed-author:CavalliFranco... | lld:pubmed |
pubmed-article:11895791 | pubmed:author | pubmed-author:ZuccaEmanuele... | lld:pubmed |
pubmed-article:11895791 | pubmed:author | pubmed-author:United... | lld:pubmed |
pubmed-article:11895791 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:11895791 | pubmed:day | 1 | lld:pubmed |
pubmed-article:11895791 | pubmed:volume | 99 | lld:pubmed |
pubmed-article:11895791 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:11895791 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:11895791 | pubmed:pagination | 2541-4 | lld:pubmed |
pubmed-article:11895791 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
pubmed-article:11895791 | pubmed:meshHeading | pubmed-meshheading:11895791... | lld:pubmed |
pubmed-article:11895791 | pubmed:meshHeading | pubmed-meshheading:11895791... | lld:pubmed |
pubmed-article:11895791 | pubmed:meshHeading | pubmed-meshheading:11895791... | lld:pubmed |
pubmed-article:11895791 | pubmed:meshHeading | pubmed-meshheading:11895791... | lld:pubmed |
pubmed-article:11895791 | pubmed:meshHeading | pubmed-meshheading:11895791... | lld:pubmed |
pubmed-article:11895791 | pubmed:meshHeading | pubmed-meshheading:11895791... | lld:pubmed |
pubmed-article:11895791 | pubmed:meshHeading | pubmed-meshheading:11895791... | lld:pubmed |
pubmed-article:11895791 | pubmed:meshHeading | pubmed-meshheading:11895791... | lld:pubmed |
pubmed-article:11895791 | pubmed:meshHeading | pubmed-meshheading:11895791... | lld:pubmed |
pubmed-article:11895791 | pubmed:meshHeading | pubmed-meshheading:11895791... | lld:pubmed |
pubmed-article:11895791 | pubmed:meshHeading | pubmed-meshheading:11895791... | lld:pubmed |
pubmed-article:11895791 | pubmed:meshHeading | pubmed-meshheading:11895791... | lld:pubmed |
pubmed-article:11895791 | pubmed:meshHeading | pubmed-meshheading:11895791... | lld:pubmed |
pubmed-article:11895791 | pubmed:meshHeading | pubmed-meshheading:11895791... | lld:pubmed |
pubmed-article:11895791 | pubmed:year | 2002 | lld:pubmed |
pubmed-article:11895791 | pubmed:articleTitle | Molecular follow-up in gastric mucosa-associated lymphoid tissue lymphomas: early analysis of the LY03 cooperative trial. | lld:pubmed |
pubmed-article:11895791 | pubmed:affiliation | Department of Experimental Haematology, Barts and The London-Queen Mary's School of Medicine and Dentistry, London, United Kingdom. frbertoni@tin.it | lld:pubmed |
pubmed-article:11895791 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:11895791 | pubmed:publicationType | Clinical Trial | lld:pubmed |
pubmed-article:11895791 | pubmed:publicationType | Controlled Clinical Trial | lld:pubmed |
pubmed-article:11895791 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
pubmed-article:11895791 | pubmed:publicationType | Multicenter Study | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11895791 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11895791 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11895791 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11895791 | lld:pubmed |